Stock Market & Financial Investment News

News Breaks January 22, 2013 07:00 EDT CBST Cubist 2013 guidance likely to disappoint investors, says Cantor Cantor expects Cubist to provide weaker than expected 2013 guidance, as the firm thinks that estimates for U.S. sales of the company's Cubicin drug are too high. The firm believes that the company may announce another co-promote partnership this year, but it maintains a Sell rating on the shares. News For CBST From The Last 14 Days Check below for free stories on CBST the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 24, 2013 11:28 EDT CBST Options with decreasing implied volatility: WCRX P CBST NTI BBY PXP 10:04 EDT CBST On The Fly: Analyst Downgrade Summary Subscribe for More Information 07:22 EDT CBST Cubist downgraded at Janney Capital As previously reported, Janney Capital downgraded Cubist to Neutral from Buy. The firm downgraded shares due to valuation following positive news on the Markman hearings. Price target raised to $55 from $50. 06:32 EDT CBST Cubist downgraded to Neutral from Buy at Janney Capital Subscribe for More Information May 23, 2013 11:37 EDT CBST Options with decreasing implied volatility: WCRX CBST NTI BBY TSLA May 22, 2013 12:08 EDT CBST Options with decreasing implied volatility: ARNA SGMO NTAP CBST GDI May 21, 2013 10:00 EDT CBST On The Fly: Analyst Upgrade Summary Subscribe for More Information 07:17 EDT CBST Cubist price target raised to $63 from $53 at RBC Capital Subscribe for More Information 06:33 EDT CBST Cubist upgraded to Hold from Sell at Cantor Subscribe for More Information May 20, 2013 15:56 EDT CBST Cubist move higher attributed to patent construction in suit against Hospira Subscribe for More Information 15:42 EDT CBST Cubist options active on speculation of a favorable patent ruling Cubist (CBST) June 55 calls and June 47 puts are active on total call volume of 3K contracts (3K puts). June call option implied volatility is at 37, August is at 40; compared to its 26-week average of 36 according to Track Data. Active option volume suggests traders taking positions for movement on speculation of a favorable patent ruling vs.Hospira (HSP). 15:28 EDT CBST Rumor: Cubist up on speculation of a favorable patent ruling vs.Hospira May 17, 2013 05:51 EDT CBST Stocks with implied volatility movement; CBST CELG Subscribe for More Information May 16, 2013 07:29 EDT CBST Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. May 15, 2013 17:46 EDT CBST SAC Capital gives quarterly update on stakes NEW STAKES: Discovery (DISCA), Liberty Global (LBTYA), Liberty Media (LMCA), Norwegian Cruise Line (NCLH), and Cubist (CBST). INCREASED STAKES: Suncor (SU), EQT Corporation (EQT), Amazon.com (AMZN), Visa (V), and GNC Holdings (GNC). DECREASED STAKES: News Corp. (NWSA), Facebook (FB), Sherwin-Williams (SHW), and Avago (AVGO). LIQUIDATED STAKES: Coach (COH), Dover (DOV), and Virgin Media (VMED), . 16:00 EDT CBST Optimer calls active following takeover report Optimer (OPTR) May and June 17 calls are active on 5,600 contracts (500 puts) according to Track Data. Traders are taking positions for large price movement on Cubist (CBST) offered to buy the company for $20 per share, Reuters says. 15:54 EDT CBST Optimer up 12.5%, to $16.03 after Reuters report Cubist offered $20 per share Subscribe for More Information 15:53 EDT CBST Cubist offered to buy Optimer for $20 per share, Reuters says Subscribe for More Information May 13, 2013 16:53 EDT CBST Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link 15:55 EDT CBST Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.